Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Atrial Natriuretic Peptide (ANP), rat: Precision Peptide ...

    2026-03-27

    Atrial Natriuretic Peptide (ANP), rat: Precision Peptide for Blood Pressure and Cardiovascular Homeostasis Studies

    Executive Summary: Atrial Natriuretic Peptide (ANP), rat (C49H84N20O15S), is a 28-amino acid peptide hormone directly synthesized and secreted by atrial myocytes in response to atrial stretch and neurohormonal stimuli (APExBIO product). ANP exerts potent vasodilatory and natriuretic effects, contributing critically to blood pressure regulation and fluid-electrolyte homeostasis in mammalian systems (BNP1-32.com). Mechanistic studies confirm that ANP acts through guanylate cyclase-coupled natriuretic peptide receptors, leading to cGMP-mediated signaling cascades. The APExBIO rat ANP (SKU A1009) is supplied at >95% purity, enabling reproducible cardiovascular, renal, and adipose tissue metabolism research (Lamin Fragment). Use of this reagent supports robust blood pressure, natriuresis, and metabolic assay design for both in vitro and in vivo models.

    Biological Rationale

    Atrial Natriuretic Peptide (ANP) is an endogenous polypeptide hormone (28 residues) first characterized in rodent cardiac tissue. It is encoded in the rat by the NPPA gene and is stored in atrial myocyte granules. ANP is released in response to acute atrial distension, increased blood volume, angiotensin II, endothelin-1, and heightened sympathetic activity (Big Endothelin-1). This peptide plays a central physiological role in regulating blood pressure, sodium excretion (natriuresis), diuresis, and lipid mobilization. The hormone's actions are crucial for maintaining cardiovascular and renal equilibrium, especially under conditions of volume overload or hypertension. ANP's homeostatic functions are highly conserved among mammals, making rat-derived preparations directly relevant for translational cardiovascular studies. In addition, ANP intersects with pathways implicated in neurohormonal regulation, such as the renin-angiotensin-aldosterone system (RAAS), and modulates adipose tissue metabolism. The high-purity APExBIO ANP peptide enables controlled mechanistic and pharmacological assays designed to dissect these homeostatic circuits.

    Mechanism of Action of Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat

    The ANP peptide exerts its effects primarily by binding to natriuretic peptide receptor-A (NPR-A), a membrane-bound guanylate cyclase. Ligand binding stimulates the conversion of GTP to cGMP, which acts as a second messenger to induce downstream protein kinase G (PKG) activation. This pathway results in smooth muscle relaxation (vasodilation), increased glomerular filtration rate (GFR), and reduced sodium reabsorption in renal tubules (Zhang et al., 2022). The physiological outcomes include decreased systemic vascular resistance, natriuresis, diuresis, and lower circulating blood pressure. ANP also inhibits renin and aldosterone secretion, further limiting sodium retention and volume expansion. Additionally, ANP promotes lipolysis in adipose tissue by enhancing hormone-sensitive lipase activity, contributing to metabolic regulation. The precise mechanism is best studied using high-purity ANP available from APExBIO, ensuring minimal batch variability and accurate dose-response relationships in preclinical studies.

    Evidence & Benchmarks

    • ANP induces rapid natriuresis and diuresis in rodent models, reducing blood pressure within 10–30 minutes of administration (Zhang et al., 2022, DOI).
    • APExBIO's rat ANP (A1009) demonstrates >95.9% purity by HPLC and mass spectrometry, supporting reproducible assay results (APExBIO).
    • ANP inhibits aldosterone and renin release, modulating the renin-angiotensin-aldosterone system to prevent volume overload (BNP1-32.com).
    • High-dose ANP (≥10 μg/kg) in rodent studies leads to significant reductions in plasma sodium and blood pressure (Zhang et al., 2022, DOI).
    • ANP acts as a vasodilator by stimulating NPR-A/cGMP/PKG signaling in vascular smooth muscle cells (Lamin Fragment).

    Applications, Limits & Misconceptions

    ANP is widely used in cardiovascular, renal, and metabolic research. Applications include:

    • Blood pressure regulation assays in animal models and ex vivo vascular preparations
    • Natriuresis and diuresis mechanism studies in renal physiology
    • Adipose tissue metabolism and lipolysis experiments
    • Interaction studies with RAAS, endothelin, and sympathetic pathways
    • Cardiovascular disease and heart failure models to evaluate therapeutic modulation

    This article extends prior guides (Vasonatrin-Peptide.com) by detailing updated purity specifications, expanded solubility data, and new workflow integration strategies for APExBIO's A1009 ANP reagent.

    Common Pitfalls or Misconceptions

    • ANP is not effective as a direct therapy for chronic hypertension in humans; its rapid metabolism limits duration of action.
    • Peptide storage in solution at >–20°C leads to rapid degradation; long-term stability is only assured as a solid at –20°C.
    • ANP's effects are species-specific; human and rat ANP differ at several residues, affecting receptor affinity and pharmacokinetics.
    • In vitro studies require careful control of peptide concentration and buffer composition, as high DMSO (>0.5%) can disrupt cell membranes.
    • ANP does not act via the TLR4/NF-κB pathway implicated in neuroinflammation; its mechanism is distinct from adiponectin's anti-inflammatory effects (see Zhang et al., 2022, DOI).

    Workflow Integration & Parameters

    APExBIO's Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat (SKU A1009), is provided in lyophilized form at >95.9% purity. Optimal solubility is achieved at ≥122.5 mg/mL in DMSO or ≥43.5 mg/mL in water, but the peptide is insoluble in ethanol. Prepare fresh solutions immediately before use; long-term storage in solution is not recommended. For in vivo dosing, dissolve in sterile saline or compatible buffer. Store lyophilized aliquots at –20°C. Shipping is on blue ice to maintain stability. Bench protocols should follow validated guidelines for cardiovascular and renal assays (Big Endothelin-1). This resource clarifies differences from alternative peptide lots and expands upon workflow troubleshooting compared to other reviews (Lamin Fragment).

    Conclusion & Outlook

    Atrial Natriuretic Peptide (ANP), rat, as supplied by APExBIO, is a high-purity, research-grade peptide enabling reproducible investigation of natriuretic, diuretic, and vasodilatory mechanisms in cardiovascular and renal physiology. Its validated molecular integrity, solubility profile, and robust shipment ensure suitability for mechanistic, pharmacological, and translational studies. Future applications may include combinatorial assays with other neurohormonal peptides and detailed exploration of ANP's metabolic effects in disease models. For further details and ordering, visit the Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat product page.